Particle.news

Download on the App Store

Merck Lowers 2025 Profit Forecast as Tariffs and Licensing Costs Weigh

Despite beating Q1 earnings expectations, Merck adjusted its annual EPS guidance downward due to $200 million in tariff costs and a one-time charge tied to a licensing deal.

Merck logo is seen in this illustration taken March 26, 2025. REUTERS/Dado Ruvic/Illustration
Image

Overview

  • Merck reported Q1 adjusted earnings of $2.22 per share, surpassing analysts' expectations of $2.14, with revenue reaching $15.53 billion, above the forecasted $15.3 billion.
  • The company revised its 2025 adjusted earnings per share guidance to $8.82–$8.97, down from the previous range of $8.88–$9.03, while maintaining its revenue forecast of $64.1–$65.6 billion.
  • Tariff-related costs, estimated at $200 million, and a one-time 6 cent per share charge linked to a licensing agreement with Hengrui Pharma were cited as key factors for the lowered outlook.
  • Sales of Gardasil, Merck’s HPV vaccine, fell 41% year-over-year to $1.33 billion following the suspension of shipments to China due to weak demand and regulatory challenges.
  • Merck highlighted growth in its animal health division, which posted a 5% increase in sales to $1.59 billion, and noted strong contributions from recently launched products like Winrevair and Capvaxive.